Its platform technologies include The Lung Subtype Platform (LSP) which stratifies lung cancer patients into subtypes and the Hypoxia Signature which identifies patients that respond to anti-angiogenesis therapies. GeneCentric partners with clinical laboratories, pharmaceutical, and biotech companies to focus on its core strength of exceptional science and clinical studies to build evidence for the utility of its unique assays.